Favorable outcome would contribute to significantly containing the Roundup litigation as the company continues its multi-pronged strategy
The randomized, double-blind, placebo-controlled Phase 2b VITAL trial enrolled 91 patients with newly diagnosed Stage IIIb–IV epithelial ovarian cancer
The BEAR Implant is the first sports medicine device to carry a label claim related to lowering PTOA risk
UNLOXCYT is an evolution in checkpoint inhibition and is now available for the treatment of adults in the U.S. with mCSCC or laCSCC who are not candidates for curative surgery or curative radiation
The launch of PatroLab is a pivotal milestone, marking a paradigm shift in biologics development and manufacturing
The researchers removed a chemical group commonly used in previous NK1R drugs and replaced it with a novel molecular scaffold
The deal to acquire AT-01 (124-Iodine-evuzamitide) and AT-05 (PAR-Peptide + technetium-99m) underscores Bayer’s commitment to expanding in molecular imaging and advancing precision cardiology
Experts caution that realizing AI’s potential requires careful management and risk mitigation
The partnership will launch a Phase 1b cohort within Boehringer’s ongoing Beamion-BCGC1 trial
Subscribe To Our Newsletter & Stay Updated
